Welcome to our dedicated page for Liquidia SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liquidia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liquidia's regulatory disclosures and financial reporting.
Canaan VIII LP reported a proposed sale of 200,000 shares of common stock of LQDA via a Form 144 notice. The filing lists multiple sales by Canaan VIII LP during the prior three months, including 115,200 shares on 06/08/2026 and 318,893 shares on 05/11/2026. Broker/intermediary information shows UBS Financial Services Inc as the broker-dealer handling the transaction.
LQDA submitted a notice under Form 144 reporting the proposed sale of 200,000 shares of Common Stock through Fidelity Brokerage Services LLC with a transaction date of 06/04/2026. The filing lists prior issuances of 100,000 shares in a Registered Direct Offering on 04/13/2022 and 100,000 shares in a Private Investment in Public Equity on 12/27/2019.
The filing shows execution via Nasdaq and records holder and quantity details; no proceeds, price, or sales completed in the past three months are disclosed in the excerpt.
LQDA Rule 144 notice reports proposed resale of common stock. The filing lists 200,000 shares associated with UBS Financial Services and shows shares outstanding 88,114,400 as of 06/04/2026. It also records a prior sale of 318,893 shares by Canaan VIII LP on 05/11/2026.
Liquidia Corp’s Chief Human Resource Officer Sarah Krepp reported a small open-market sale of common stock. On June 1, 2026, she sold 276 shares at $60.87 per share in a transaction classified as an open-market sale.
According to the footnotes, the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023 and was specifically to cover taxes tied to the settlement of previously granted RSUs. After this transaction, Krepp holds 146,743 shares directly, including substantial unvested RSUs and shares acquired under the company’s employee stock purchase plan.
Liquidia Corp director Arthur S. Kirsch, through a revocable trust, reported open-market sales of an aggregate 30,000 shares of Liquidia common stock. The trust sold 15,000 shares on June 1, 2026 at a reported volume-weighted average price of about $60.22 per share, with a footnote stating trade prices ranged from $59.90 to $60.75.
The trust then sold 5,000 shares on June 2, 2026 at $56.00 per share and 10,000 shares on June 3, 2026 at $54.80 per share, leaving the trust with 0 indirectly held shares. A separate holding entry shows Kirsch with 40,755 shares held directly as of June 1, 2026.
Liquidia Corp Chief Executive Officer Roger Jeffs reported an open-market sale of 6,428 shares of common stock at a volume-weighted average price of $62.183 per share. The sale was executed indirectly through Serendipity BioPharma LLC pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025.
Following the sale, Serendipity BioPharma LLC held 1,041,667 shares indirectly for Jeffs, in addition to 1,137,508 shares held directly and 46,595 shares held through the Roger A. Jeffs Living Trust. Jeffs also holds unvested restricted stock units granted between January 2023 and January 2026 that had not vested as of this Form 4.
Liquidia Corp director Raman Singh reported an exercise-and-sell transaction in company stock. On May 21, 2026, he sold 29,494 shares of Common Stock in an open-market sale at a volume-weighted average price of $60.1287, representing the subsequent sale of shares acquired from option exercises reported in the same filing.
That day he exercised stock options covering 10,050 shares at $11.00 per share and 19,444 shares at $8.63 per share. After these transactions, he directly holds 38,755 Common shares and has 18,396 restricted stock units that were granted on June 17, 2025 and have not yet vested.
Liquidia Corp Chief Executive Officer Roger Jeffs reported open-market sales of 75,000 shares of Common Stock across three transactions on May 21, 2026, May 22, 2026, and May 26, 2026. The sales were executed at volume-weighted average prices of $61.1264, $61.5222, and $60.3784 per share, respectively, and were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025.
The sold shares are reported as indirectly owned through entities including the Roger A. Jeffs Living Trust and Serendipity BioPharma LLC, where Jeffs has voting and dispositive power. After the most recent transaction, indirect holdings are reported at 1,048,095 shares, and a separate direct holding entry on May 21, 2026 shows 1,137,508 shares. Jeffs also holds multiple grants of unvested restricted stock units totaling more than 400,000 RSUs that have not yet vested.
Ramandeep Singh filed a Form 144 notifying the proposed sale of 29,494 shares of common stock via a stock option exercise to occur on 05/21/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker-dealer and Nasdaq as the market.
The notice also records a prior sale of 40,359 shares on 03/13/2026 for $1,457,296.50.